WM STUDY NOW ENROLLING!

Are You Living with Waldenström Macroglobulinemia (WM)?

WM clinical research study seeks volunteers

A clinical research study, or clinical trial, is now enrolling people living with Waldenström Macroglobulinemia (WM) who have both *MYD88* and *CXCR4* genetic variants, or mutations.

About the study

This study will help researchers answer questions about the drug mavorixafor.

Mavorixafor pills are taken by mouth.

In earlier studies, mavorixafor was well tolerated in over 200 people, including healthy volunteers and people with cancer or primary immunodeficiencies.

This is a Phase 1b study, which means participants with WM can help researchers learn what dosage of mavorixafor is well-tolerated in combination with ibrutinib.

Everyone in this study will take varying doses of mavorixafor along with ibrutinib, an FDA-approved treatment for WM.

Why participate in a clinical study?

- More treatment options are needed for people living with WM with both *MYD88*^{L265P} and *CXCR4*^{WHIM} genetic variants.
- People who join this study will have frequent check-ups to watch for any changes in health.
- Before the FDA can approve a treatment, clinical studies must show that a drug is safe and works for the people it is intended to treat.

Study details

Duration:
The study will last about 2 years.

Cost:
There is no cost for people in the study. Treatment, travel and lodging costs are covered by X4 Pharmaceuticals.

Study sponsor:
X4 Pharmaceuticals is conducting the trial in collaboration with The Leukemia & Lymphoma Society.

Study sites:
Medical study centers are in Boston, Denver and Houston, and the study may involve home health care and virtual check-ups.

Who can join?

- Adults over the age of 18
- People with a WM diagnosis with both *MYD88*^{L265P} and *CXCR4*^{WHIM} genetic variants
- People who have had no treatment for WM or people who have had up to three treatments for WM
- People who have never taken a CXCR4 inhibitor or a BTK inhibitor
- There are other criteria to join the study

Talk to your doctor to find out if this study is a good option for you.

Email
patientinfo@x4pharma.com

Visit
www.WMTrial.com

References

Castillo JJ, Xu L, Gustine JN, et al. CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. Br J Haematol. 2019;187(3):356-363. doi:10.1111/bjh.16088

Search ClinicalTrials.gov for NCT04274738